Comparative Pharmacology
Head-to-head clinical analysis: SYMBYAX versus TIAMATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYMBYAX versus TIAMATE.
SYMBYAX vs TIAMATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Symbyax is a combination of olanzapine (an atypical antipsychotic) and fluoxetine (a selective serotonin reuptake inhibitor). Olanzapine antagonizes dopamine D2, serotonin 5-HT2A, and other CNS receptors; fluoxetine inhibits serotonin reuptake. Synergy targets depressive and manic symptoms via dopaminergic and serotonergic modulation.
Tiamate is a combination of tiamulin (a pleuromutilin antibiotic) and valnemulin (a pleuromutilin antibiotic). Tiamulin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically at the peptidyl transferase center, preventing peptide bond formation. Valnemulin similarly binds to the 50S subunit and inhibits protein synthesis.
6 mg/25 mg to 12 mg/50 mg orally once daily; maximum 12 mg/50 mg per day.
250 mg orally twice daily
None Documented
None Documented
Olanzapine: 21-54 h (mean 30 h in adults; longer in elderly and hepatic impairment). Fluoxetine: 4-6 days (norfluoxetine 4-16 days). Extensive accumulation with chronic dosing; steady-state reached in 2-4 weeks for fluoxetine.
Terminal half-life 2–4 hours; dose adjustment needed in renal impairment (CrCl <30 mL/min)
Olanzapine: ~57% renal (7% unchanged, rest as metabolites; 30% fecal as metabolites from biliary excretion). Fluoxetine: ~60% renal (primarily as metabolites; <10% unchanged) and ~40% fecal (via biliary excretion of metabolites).
Primarily renal (70–80% as unchanged drug); biliary/fecal (20–30%)
Category C
Category C
Antidepressant/Antipsychotic Combination
Antidepressant